02:15 , Dec 16, 2017 |  BioCentury  |  Product Development

Assessing the BCMA scene

Differences in patient populations and a dearth of clinical outcome data mean it’s too soon to declare bluebird bio Inc.’s anti-BCMA chimeric antigen receptor therapy the leader of the pack of CARs that presented clinical...
16:22 , Dec 15, 2017 |  BC Week In Review  |  Clinical News

Syros discontinues single agent tamibarotene

Syros Pharmaceuticals Inc. (NASDAQ:SYRS) said only one of 48 evaluable patients receiving tamibarotene (SY-1425) as monotherapy achieved a complete response in a Phase II trial to treat relapsed or refractory acute myelogenous leukemia (AML) and...
23:07 , Dec 11, 2017 |  BC Extra  |  Clinical News

Syros falls on Phase II AML, MDS data

Syros Pharmaceuticals Inc. (NASDAQ:SYRS) lost $3.92 (32%) to $8.45 on Monday after reporting that only one of 48 evaluable patients receiving tamibarotene (SY-1425) as monotherapy achieved a complete response in a Phase II trial to...
21:27 , Oct 26, 2017 |  BC Innovations  |  Tools & Techniques

Ripe for enhancement

Although still largely the purview of academics, technologies for mapping enhancers to the genes they control are rapidly gaining efficiency and promise to unlock a trove of new targets for drug developers. But companies will...
19:58 , Sep 21, 2017 |  BC Innovations  |  Tools & Techniques

On your marks

With less fanfare than the first two waves, a quiet rise in activity is driving a revival of interest in epigenetics, despite little progress in solving the fundamental challenges that have dogged the field from...
22:44 , Apr 21, 2017 |  BC Extra  |  Financial News

Syros, SteadyMed complete private placements

Cancer company Syros Pharmaceuticals Inc. (NASDAQ:SYRS) and drug delivery play SteadyMed Ltd. (NASDAQ:STDY) raised a total of $65 million in private placements on Friday. Syros raised $35 million through the sale of 2.6 million shares...
14:22 , Apr 18, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Stroke Mouse studies suggest promoting MSR-1 expression could help treat ischemic stroke. MSR-1 levels were higher in brain-derived myeloid cells from a mouse model of ischemic stroke than cells from normal mice. In the...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Clinical News

Tamibarotene: Phase II started

Syros began an open-label, U.S. Phase II trial evaluating 3 mg/m 2 oral tamibarotene twice daily in 28-day cycles in about 40 patients with a biomarker associated with the RARA pathway. Syros has exclusive rights...
01:06 , Jul 1, 2016 |  BC Extra  |  Financial News

Syros rises after $50M IPO

Syros Pharmaceuticals Inc. (NASDAQ:SYRS) gained $5.65 (45%) to $18.15 on its first day of trading Thursday after raising $50 million through the sale of 4 million shares at $12.50 in an IPO. The price valued...
01:30 , Jan 14, 2016 |  BC Extra  |  Financial News

Gene control play Syros raises $40M

Syros Pharmaceuticals Inc. (Watertown, Mass.) raised $40 million in a venture round led by Deerfield Management. Fellow new investor Casdin Capital also participated, as did existing investors Fidelity, WuXi Healthcare Ventures, Polaris Partners, Redmile Group,...